Loading...
XHKG
1875
Market cap159mUSD
Apr 11, Last price  
1.71HKD
1D
0.59%
1Q
-5.00%
IPO
-72.33%
Name

TOT BIOPHARM International Co Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
1.49
EPS
—
Div Yield, %
—
Shrs. gr., 5y
4.93%
Rev. gr., 5y
81.88%
Revenues
1.10b
+40.70%
51,608,00039,219,00045,308,00022,491,00076,325,000442,178,000780,629,0001,098,329,000
Net income
35m
P
-148,687,000-268,263,000-331,179,000-288,498,000-261,216,000-49,916,000-37,757,00034,757,000
CFO
0k
-100.00%
-117,388,000-176,832,000-251,329,000-263,116,000-175,137,00059,929,00056,431,0000
Earnings
Aug 11, 2025

Profile

TOT BIOPHARM International Company Limited, an investment holding company, engages in the research and development, manufacture, and marketing of anti-tumor drugs in the People's Republic of China. The company's principal drug candidate is TAB008 for the treatment of non-squamous non-small-cell lung cancer metastatic colorectal cancer, glioblastoma multiforme, ovarian cancer, cervical cancer, and hepatocellular carcinoma. It also offers TOZ309 for malignant brain tumor. Further, the company develops TAA013 for HER2+ breast cancer which is under Phase III clinical trial; TAE020 which is under preclinical trial for acute myeloid leukemia; TAB014 for wet age-related macular degeneration and is under Phase II clinical trial. In addition, it develops TAY018 for non-Hodgkin's lymphoma, myelodysplastic syndrome, acute myelogenous leukemia, and solid tumors; TAC020 for various solid tumors; TEP118 for biliary cancer, gallbladder tumors, metastatic cancer, non-small-cell lung cancer (NSCLC), and gastric cancer; TOM312 for cancer and HIV-associated cachexia; TIC318 for epithelial-derived ovarian cancer, small-cell lung cancer, head and neck squamous cell carcinoma, testicular tumors, malignant lymphoma, cervical cancer, bladder cancer, and NSCLC; TVP211 and TID214 for solid tumors; and TIO217 for gastrointestinal tumors. TOT BIOPHARM International Company Limited was incorporated in 2009 and is headquartered in Suzhou, the People's Republic of China.
URL
https://www.totbiopharm.cn/
IPO date
Nov 08, 2019
Employees
431
Domiciled in
CN
Incorporated in
HK

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
1,098,329
40.70%
780,629
76.54%
442,178
479.34%
Cost of revenue
1,083,296
819,862
489,272
Unusual Expense (Income)
NOPBT
15,033
(39,233)
(47,094)
NOPBT Margin
1.37%
Operating Taxes
1,000
(2,599)
Tax Rate
NOPAT
15,033
(39,234)
(44,495)
Net income
34,757
-192.05%
(37,757)
-24.36%
(49,916)
-80.89%
Dividends
Dividend yield
Proceeds from repurchase of equity
405,788
BB yield
-26.45%
Debt
Debt current
70,866
42,772
77,051
Long-term debt
326,057
304,245
214,374
Deferred revenue
11,000
Other long-term liabilities
39,152
54,050
58,767
Net debt
15,667
(11,347)
(129,525)
Cash flow
Cash from operating activities
56,431
59,929
CAPEX
(197,281)
(240,123)
Cash from investing activities
(164,105)
(282,764)
Cash from financing activities
38,225
481,240
FCF
(28,983)
(186,484)
(221,522)
Balance
Cash
381,256
358,364
458,047
Long term investments
(37,097)
Excess cash
326,340
319,333
398,841
Stockholders' equity
729,655
614,214
715,439
Invested Capital
837,935
767,054
673,357
ROIC
1.87%
ROCE
1.29%
EV
Common stock shares outstanding
725,197
725,197
639,307
Price
1.79
-9.14%
1.97
-17.92%
2.40
 
Market cap
1,298,103
-9.14%
1,428,638
-6.89%
1,534,337
 
EV
1,313,770
1,417,291
1,406,369
EBITDA
15,033
3,795
(9,055)
EV/EBITDA
87.39
373.46
Interest
5,175
6,602
Interest/NOPBT